Yousif Capital Management LLC Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Yousif Capital Management LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,777 shares of the company’s stock after selling 172 shares during the quarter. Yousif Capital Management LLC’s holdings in Krystal Biotech were worth $1,532,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Segall Bryant & Hamill LLC increased its stake in Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after buying an additional 122,407 shares during the period. State Street Corp grew its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after acquiring an additional 62,178 shares during the period. Braidwell LP raised its stake in shares of Krystal Biotech by 57.4% in the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after acquiring an additional 61,512 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in Krystal Biotech in the third quarter valued at $5,872,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Chardan Capital restated a “buy” rating and set a $212.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $206.67.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Up 0.9 %

Shares of Krystal Biotech stock opened at $151.32 on Thursday. Krystal Biotech, Inc. has a 52 week low of $107.50 and a 52 week high of $219.34. The firm’s 50 day moving average is $160.45 and its two-hundred day moving average is $176.84. The firm has a market capitalization of $4.35 billion, a P/E ratio of 85.49 and a beta of 0.84.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).